Evotec SE (EVO) announced progress within the strategic partnership with Bristol Myers Squibb. Evotec received a $25 million payment to progress further research. A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. A Phase II study for BMS-986419 is scheduled to commence in 2024.
The companies entered their strategic neuroscience collaboration in December 2016. In March 2023, the companies extended and expanded the partnership for an additional 8 years.
Cord Dohrmann, Chief Scientific Officer of Evotec, said: "As the first asset from our neuroscience partnership with Bristol Myers Squibb is moving towards a Phase II study, our partnership is still growing in the drug discovery phase as well."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.